MX2017015424A - Nanoparticulas para su uso como vacuna terapeutica. - Google Patents

Nanoparticulas para su uso como vacuna terapeutica.

Info

Publication number
MX2017015424A
MX2017015424A MX2017015424A MX2017015424A MX2017015424A MX 2017015424 A MX2017015424 A MX 2017015424A MX 2017015424 A MX2017015424 A MX 2017015424A MX 2017015424 A MX2017015424 A MX 2017015424A MX 2017015424 A MX2017015424 A MX 2017015424A
Authority
MX
Mexico
Prior art keywords
nanoparticles
therapeutic vaccine
cancer
radiotherapy
context
Prior art date
Application number
MX2017015424A
Other languages
English (en)
Spanish (es)
Inventor
Levy Laurent
Marill Julie
Pottier Agnés
Original Assignee
Nanobiotix
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanobiotix filed Critical Nanobiotix
Publication of MX2017015424A publication Critical patent/MX2017015424A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/242Gold; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/5115Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/10X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/10X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092Details
    • A61N2005/1098Enhancing the effect of the particle by an injected agent or implanted device

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2017015424A 2015-05-28 2016-05-27 Nanoparticulas para su uso como vacuna terapeutica. MX2017015424A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15305810 2015-05-28
PCT/EP2016/061989 WO2016189125A1 (en) 2015-05-28 2016-05-27 Nanoparticles for use as a therapeutic vaccine

Publications (1)

Publication Number Publication Date
MX2017015424A true MX2017015424A (es) 2018-03-01

Family

ID=53298299

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017015424A MX2017015424A (es) 2015-05-28 2016-05-27 Nanoparticulas para su uso como vacuna terapeutica.
MX2023007706A MX2023007706A (es) 2015-05-28 2017-11-28 Nanoparticulas para su uso como vacuna terapeutica.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023007706A MX2023007706A (es) 2015-05-28 2017-11-28 Nanoparticulas para su uso como vacuna terapeutica.

Country Status (18)

Country Link
US (2) US11096962B2 (https=)
EP (1) EP3302419B1 (https=)
JP (2) JP2018516256A (https=)
KR (1) KR102727195B1 (https=)
CN (2) CN118286421A (https=)
AR (1) AR104806A1 (https=)
AU (2) AU2016269146B2 (https=)
BR (1) BR112017025553A2 (https=)
EA (1) EA201792560A1 (https=)
HK (1) HK1246160A1 (https=)
IL (1) IL255853B (https=)
MA (1) MA43100A (https=)
MX (2) MX2017015424A (https=)
NZ (1) NZ738527A (https=)
TW (2) TWI910445B (https=)
UA (1) UA124572C2 (https=)
WO (1) WO2016189125A1 (https=)
ZA (1) ZA201708686B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3424533A1 (en) * 2017-07-05 2019-01-09 Nh Theraguix Methods for treating tumors
CN109010828B (zh) * 2018-10-12 2020-10-20 中国科学院高能物理研究所 一种二硫化钼/二氧化铪的复合纳米材料、其制备方法及用途
EP3866832B1 (en) 2018-10-19 2024-12-11 University of Rochester Immunomodulatory cytokines in combination with radiation treatment for unresectable pancreatic cancer
CN116507366A (zh) * 2020-11-05 2023-07-28 纳米生物技术公司 用于治疗癌症的纳米颗粒组合物
AR131316A1 (es) 2022-12-12 2025-03-05 Nanobiotix S A Novedosas nanopartículas de óxido de metal y composiciones de las mismas para uso como radiopotenciadores o para visualizar tejido biológico
CN116370625B (zh) * 2023-03-14 2024-10-11 浙江大学 一种哑铃状的金-氧化铈纳米材料的制备方法及其产品和应用

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4280918A (en) 1980-03-10 1981-07-28 International Business Machines Corporation Magnetic particle dispersions
US4672040A (en) 1983-05-12 1987-06-09 Advanced Magnetics, Inc. Magnetic particles for use in separations
US4770183A (en) 1986-07-03 1988-09-13 Advanced Magnetics Incorporated Biologically degradable superparamagnetic particles for use as nuclear magnetic resonance imaging agents
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US6099457A (en) 1990-08-13 2000-08-08 Endotech, Inc. Endocurietherapy
US5370901A (en) 1991-02-15 1994-12-06 Bracco International B.V. Compositions for increasing the image contrast in diagnostic investigations of the digestive tract of patients
WO1993026019A1 (en) 1992-06-08 1993-12-23 Molecular Bioquest, Inc. Preparation of controlled size inorganic particles for use in separations, as magnetic molecular switches, and as inorganic liposomes for medical applications
EP0654973A4 (en) 1992-07-21 1995-08-09 Gen Hospital Corp ARRANGEMENT FOR DELIVERING MEDICINES TO THE LYMPHIC TISSUE.
US5395619A (en) 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
WO1995022963A1 (en) 1994-02-28 1995-08-31 Medinova Medical Consulting Gmbh Drug targeting system, method for preparing same and its use
GB9509321D0 (en) 1995-05-09 1995-06-28 Zylepsis Ltd Methods of and substances for inhibiting oxidative enzymes
JPH10120597A (ja) 1996-10-22 1998-05-12 Eiken Chem Co Ltd リンパ節高集積性コロイド粒子
DE19716732C2 (de) 1997-03-07 1999-03-25 Max Delbrueck Centrum Spezifische Magnetosomen, Verfahren zu ihrer Herstellung und ihre Verwendung
EP0971692B1 (de) 1997-03-07 2003-03-05 Max-Delbrück-Centrum Für Molekulare Medizin Spezifische magnetosomen, verfahren zu ihrer herstellung und ihre verwendung
DE19726282A1 (de) 1997-06-20 1998-12-24 Inst Neue Mat Gemein Gmbh Nanoskalige Teilchen mit einem von mindestens zwei Schalen umgebenen eisenoxid-haltigen Kern
US6161034A (en) 1999-02-02 2000-12-12 Senorx, Inc. Methods and chemical preparations for time-limited marking of biopsy sites
US6200598B1 (en) 1998-06-18 2001-03-13 Duke University Temperature-sensitive liposomal formulation
US6726925B1 (en) 1998-06-18 2004-04-27 Duke University Temperature-sensitive liposomal formulation
US6645464B1 (en) 1998-07-30 2003-11-11 James F. Hainfeld Loading metal particles into cell membrane vesicles and metal particular use for imaging and therapy
WO2001037721A2 (en) 1999-11-22 2001-05-31 The Research Foundation Of State University Of New York Magnetic nanoparticles for selective therapy
AU3679801A (en) 2000-02-08 2001-08-20 Rice University Optically-active nanoparticles for use in therapeutic and diagnostic methods
ATE320605T1 (de) 2000-05-05 2006-04-15 Dotierte nanoteilchen als biolabel
WO2002029410A2 (en) 2000-10-06 2002-04-11 Quantum Dot Corporation Cells having a spectral signature, and methods of preparation and use thereof
MXPA03004298A (es) 2000-11-20 2004-02-12 Oncolytics Biotech Inc Metodo para transmitir optimamente virus a masa de tumor solido.
US20020127224A1 (en) 2001-03-02 2002-09-12 James Chen Use of photoluminescent nanoparticles for photodynamic therapy
US6756063B2 (en) 2001-03-29 2004-06-29 Zoltan Laboratories, Llc Methods and compositions for the treatment of human and animal cancers
DE10154016B4 (de) 2001-10-26 2004-02-12 Berlin Heart Ag Magnetflüssigkeit und Verfahren zur ihrer Herstellung
WO2003075961A2 (en) 2002-03-08 2003-09-18 James Hainfeld Gold nanoparticles used for x-rays imaging
US20030191458A1 (en) 2002-04-03 2003-10-09 Cornelius Diamond Light-activated drug delivery method and device
US7769423B2 (en) 2002-09-11 2010-08-03 Duke University MRI imageable liposomes for the evaluation of treatment efficacy, thermal distribution, and demonstration of dose painting
US20030125283A1 (en) 2002-09-16 2003-07-03 Gatenby Robert A. Therapy of proliferative disorders by direct irradiation of cell nuclei with tritiated nuclear targetting agents
AU2004207813B8 (en) 2003-01-24 2010-04-22 Health Research, Inc. Use of photodynamic therapy therapeutic agents entrapped in ceramic nanoparticles
US7235228B2 (en) 2003-04-15 2007-06-26 The United States Of America As Represented By The Secretary Of The Navy Fluorescent-magnetic nanoparticles with core-shell structure
US20050084869A1 (en) 2003-10-20 2005-04-21 Sung Hyun Kim Novel composition and methods for the diagnosis of lung cancer
US20050090732A1 (en) 2003-10-28 2005-04-28 Triton Biosystems, Inc. Therapy via targeted delivery of nanoscale particles
WO2005046733A1 (en) 2003-11-17 2005-05-26 Philips Intellectual Property & Standards Gmbh Contrast agent for medical imaging techniques and usage thereof
CA2547024C (en) 2003-12-22 2013-12-17 Bracco Research Sa Gas-filled microvesicle assembly for contrast imaging
US20080193372A1 (en) 2004-02-10 2008-08-14 Barnes-Jewish Hospital Efficacy and Safety of Targeted Particulate Agents with Decoy Systems
JP4895151B2 (ja) 2004-02-27 2012-03-14 日立金属株式会社 鉄系ナノサイズ粒子およびその製造方法
FR2869803B1 (fr) 2004-05-10 2006-07-28 Nanobiotix Sarl Particules activables, preparation et utilisations
US20050260137A1 (en) 2004-05-18 2005-11-24 General Electric Company Contrast agents for magnetic resonance imaging
US20070031337A1 (en) 2004-06-22 2007-02-08 Reinhard Schulte Nanoparticle enhanced proton computed tomography and proton therapy
GB2415374A (en) 2004-06-25 2005-12-28 Leuven K U Res & Dev Targeted delivery of biologically active substances using iron oxide/gold core-shell nanoparticles
WO2006037081A2 (en) 2004-09-28 2006-04-06 The Regents Of The University Of California Nanoparticle radiosensitizers
FR2877571B1 (fr) 2004-11-05 2007-04-13 Nanobiotix Sarl Nanoparticules pourvues d'un element de ciblage intracellulaire, preparation et utilisations
WO2006051732A1 (ja) 2004-11-10 2006-05-18 Konica Minolta Medical & Graphic, Inc. 被覆磁性粒子含有製剤およびその製造方法、並びに診断治療システム
US20060264804A1 (en) 2005-04-07 2006-11-23 Yoram Karmon Device and kit for delivery of encapsulated substances and methods of use thereof
FR2884149B1 (fr) 2005-04-12 2007-06-08 Henri Mehier Tube implantable destine a l'injection notamment de fluide caloporteur dans tout ou partie d'un tissu humain ou animal
US20070092927A1 (en) 2005-06-13 2007-04-26 University Of Dayton Photocatalytic particles with directed and controlled redox activity
DE102005039579B4 (de) 2005-08-19 2022-06-30 Magforce Ag Verfahren zur Einschleusung von therapeutischen Substanzen in Zellen
US20090304587A1 (en) 2005-11-01 2009-12-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Biodegradable composite for internal local radiotherapy
US20070098640A1 (en) 2005-11-02 2007-05-03 General Electric Company Nanoparticle-based imaging agents for X-ray/computed tomography
KR100745744B1 (ko) 2005-11-11 2007-08-02 삼성전기주식회사 나노 입자 코팅 방법
WO2007122956A1 (ja) 2006-03-24 2007-11-01 Toto Ltd. 酸化チタン複合体粒子、その分散液、およびそれらの製造方法
JP2009536151A (ja) 2006-03-30 2009-10-08 富士フイルム株式会社 ナノ粒子
EP1852107A1 (en) 2006-04-19 2007-11-07 Nanobiotix Magnetic nanoparticles compositions and uses thereof
WO2007128066A1 (en) 2006-05-04 2007-11-15 University Of South Australia Drug release from nanoparticle-coated capsules
US20090191128A1 (en) 2006-07-10 2009-07-30 Koninklijke Philips Electronics N.V. Core-shell nanoparticles for thearapy and imaging purposes
DE102006041495A1 (de) 2006-08-29 2008-03-20 Friedrich-Schiller-Universität Jena Substanzgemisch zur lokalen Deposition von Magnetpartikeln in einem Medium, insbesondere in tumorbefallenem organischem Gewebe, sowie Applikationskit zur Verabreichung
NO329127B1 (no) 2006-09-12 2010-08-30 Epitarget As Sporbart partikulaert materiale for legemiddelavlevering omfattende et matriseeller membranmateriale, et legemiddel, og et T1- og et T2*- magnetisk resonanskontrastmiddel
NO20064315L (no) 2006-09-22 2008-03-24 Epitarget As T1 MRI-sporbare medikamentavleveringspartikler and anvendelse derav
IL181126A0 (en) 2006-11-01 2007-07-04 S B Biotechnologies Ltd Preparation of gold-containing nano-liposome particles and their use in medical therapy
EP1920784A1 (en) 2006-11-13 2008-05-14 Koninklijke Philips Electronics N.V. Radiation sensitizers in ionizing radiation therapy and imaging
US20090004258A1 (en) 2007-06-27 2009-01-01 National Health Research Institutes Drug Release from Thermosensitive Liposomes by Applying an Alternative Magnetic Field
CA2697042A1 (en) 2007-08-21 2009-02-26 Alza Corporation Liposome compositions for in vivo administration of boronic acid compounds
JP2009067613A (ja) 2007-09-11 2009-04-02 Fujifilm Corp コア−シェル型金属酸化物微粒子及びその製造方法
US20120176016A1 (en) 2007-09-28 2012-07-12 General Electric Company Core-shell particulates, articles, and method of making
FR2922106B1 (fr) 2007-10-16 2011-07-01 Univ Claude Bernard Lyon Utilisation de nanoparticules a base de lanthanides comme agents radiosensibilisants.
EP2067485A1 (en) 2007-12-07 2009-06-10 Koninklijke Philips Electronics N.V. Drug carrier providing MRI contrast enhancement
WO2009081287A2 (en) 2007-12-21 2009-07-02 University Of Guelph Polysaccharide nanoparticles
DE102008003615A1 (de) 2008-01-09 2009-07-16 Magforce Nanotechnologies Ag Magnetische Transducer
DE102008008522A1 (de) 2008-02-11 2009-08-13 Magforce Nanotechnologies Ag Implantierbare Nanopartikel-enthaltende Produkte
US9403789B2 (en) 2008-02-21 2016-08-02 Sequoia Pharmaceuticals, Inc. Benzofuran-containing amino acid inhibitors of cytochrome P450
DE102008000852A1 (de) 2008-03-27 2009-10-01 Bosch Mahle Turbo Systems Gmbh & Co. Kg Abgasturbolader für ein Kraftfahrzeug
WO2009142754A1 (en) 2008-05-22 2009-11-26 Goverment Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dendritic conjugates and methods of use
EP2130553A1 (en) * 2008-06-05 2009-12-09 Nanobiotix Inorganic nanoparticles of high density to destroy cells in-vivo
WO2010048623A2 (en) 2008-10-26 2010-04-29 Board Of Regents, The University Of Texas Systems Medical and imaging nanoclusters
US8395131B2 (en) 2009-06-20 2013-03-12 Xiaodong Wu Method for three dimensional (3D) lattice radiotherapy
EP2275137A1 (en) 2009-07-10 2011-01-19 Nanobiotix Metallic nanoparticles, preparation and uses thereof
EP2305310A1 (en) 2009-09-25 2011-04-06 Asociación Centro de Investigación Cooperativa en Biomateriales - CIC biomaGUNE Gold -coated magnetic glyconanoparticles functionalised with proteins for use as diagnostic and therapeutic agents
GB0921596D0 (en) 2009-12-09 2010-01-27 Isis Innovation Particles for the treatment of cancer in combination with radiotherapy
CA3149284A1 (en) 2009-12-15 2011-07-14 Incept, Llc Implants and biodegradable fiducial markers
US8580312B2 (en) 2010-02-17 2013-11-12 National University Corporation Kobe University Radiation therapy agent
NZ602382A (en) 2010-03-26 2014-11-28 Abraxis Bioscience Llc Methods of treatment of hepatocellular carcinoma
WO2011133228A2 (en) 2010-04-23 2011-10-27 Pixelligent Technologies, Llc Synthesis, capping and dispersion of nanocrystals
GB201009455D0 (en) 2010-06-04 2010-07-21 King S College London Nanoparticles and their uses in molecular imaging
US20130177523A1 (en) 2010-07-13 2013-07-11 University Of Utah Research Foundation Gold particles and methods of making and using the same in cancer treatment
WO2012048289A1 (en) 2010-10-08 2012-04-12 Board Of Regents, The University Of Texas System Anti-adhesive barrier membrane using alginate and hyaluronic acid for biomedical applications
US9782342B2 (en) 2010-10-11 2017-10-10 Wichita State University Composite magnetic nanoparticle drug delivery system
WO2012104275A2 (en) 2011-01-31 2012-08-09 Nanobiotix Nanoparticles delivery systems, preparation and uses thereof
EP2670393B8 (en) 2011-01-31 2016-10-05 Nanobiotix Method of monitoring the release from liposomes of a product of interest using superparamagnetic nanoparticles.
JP2014516960A (ja) * 2011-05-19 2014-07-17 インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル) 抗ヒトher3抗体及びその使用
WO2013059295A2 (en) 2011-10-17 2013-04-25 Trustees Of Boston University Polymeric depots for localization of an agent to biological sites
EP2782603A1 (en) 2011-11-25 2014-10-01 Danmarks Tekniske Universitet Formulation of solid nano-sized particles in a gel-forming system
EA029635B1 (ru) 2011-12-16 2018-04-30 Нанобиотикс Применение наночастицы, включающей металлический материал, покрытый материалом оксида гафния, в онкологии и композиция, ее содержащая
IN2014MN02089A (https=) 2012-03-20 2015-09-11 Einstein Coll Med
US20150209397A1 (en) 2012-09-07 2015-07-30 Carnegie Mellon University Methods and materials for reducing reticuloendothelial system clearance of particles from a subject
ITRM20120480A1 (it) 2012-10-09 2014-04-10 Uni Degli Studi Camerino Nanoparticelle lipidiche multicomponenti e procedimenti per la loro preparazione.
US20140186447A1 (en) 2012-12-28 2014-07-03 Abraxis Bioscience, Llc Nanoparticle compositions of albumin and paclitaxel
US20140213765A1 (en) 2013-01-25 2014-07-31 I-Liang Lee Albumin tissue scaffold
AR094577A1 (es) 2013-01-25 2015-08-12 Nanobiotix Composiciones para el tratamiento de cáncer, preparación y usos de las mismas
WO2014121224A2 (en) 2013-02-01 2014-08-07 The Trustees Of Dartmouth College Biodegradable iron oxide nanoparticle gel for tumor bed therapy
WO2014191569A1 (en) 2013-05-30 2014-12-04 Nanobiotix Pharmaceutical composition, preparation and uses thereof
EA201690050A1 (ru) 2013-06-20 2016-05-31 Нанобиотикс Композиции и способы для применения в медицинской диагностике
US20160136304A1 (en) 2013-06-20 2016-05-19 Nanobiotix Compositions and methods for use in oncology
EP2886128A1 (en) 2013-12-20 2015-06-24 Nanobiotix Pharmaceutical composition comprising nanoparticles, preparation and uses thereof
EP3223796B1 (en) 2014-11-25 2021-07-21 Curadigm Sas Pharmaceutical compositions, preparation and uses thereof
EP3229776B1 (en) 2014-11-25 2023-06-28 Curadigm Sas Pharmaceutical composition combining at least two distinct nanoparticles and a pharmaceutical compound, preparation and uses thereof
ES2774365T3 (es) 2014-11-25 2020-07-20 Curadigm Sas Composición farmacéutica, preparación y usos de la misma
SG11201704143YA (en) 2014-11-25 2017-06-29 Nanobiotix Pharmaceutical composition, preparation and uses thereof
UA123665C2 (uk) 2014-11-25 2021-05-12 Кюрадігм Сас Фармацевтична композиція, її одержання і застосування

Also Published As

Publication number Publication date
CA2987331A1 (en) 2016-12-01
TWI873079B (zh) 2025-02-21
JP7570134B2 (ja) 2024-10-21
AU2016269146B2 (en) 2021-01-28
AU2021202582A1 (en) 2021-05-27
TW201705977A (zh) 2017-02-16
MX2023007706A (es) 2023-07-10
EP3302419A1 (en) 2018-04-11
IL255853A (en) 2018-01-31
EP3302419B1 (en) 2026-01-21
HK1246160A1 (zh) 2018-09-07
CN107708668A (zh) 2018-02-16
EA201792560A1 (ru) 2018-06-29
TWI910445B (zh) 2026-01-01
IL255853B (en) 2020-08-31
US20210353670A1 (en) 2021-11-18
AU2021202582B2 (en) 2022-12-15
US11096962B2 (en) 2021-08-24
AU2016269146A1 (en) 2018-01-18
AR104806A1 (es) 2017-08-16
US20180147237A1 (en) 2018-05-31
NZ776598A (en) 2024-10-25
JP2023082080A (ja) 2023-06-13
ZA201708686B (en) 2025-03-26
KR102727195B1 (ko) 2024-11-06
CN118286421A (zh) 2024-07-05
BR112017025553A2 (pt) 2018-08-07
UA124572C2 (uk) 2021-10-13
TW202417036A (zh) 2024-05-01
JP2018516256A (ja) 2018-06-21
NZ738527A (en) 2022-07-01
KR20180012823A (ko) 2018-02-06
WO2016189125A1 (en) 2016-12-01
MA43100A (fr) 2018-09-05

Similar Documents

Publication Publication Date Title
JOP20200192A1 (ar) أجسام مضادة لـ tigit
CY1124436T1 (el) Δικυκλικες ετεροκυκλικες ενωσεις και χρησεις αυτων στη θεραπεια
MX2022007522A (es) Anticuerpos anti-cd27.
ES2765949T8 (es) Terapia que involucra anticuerpos contra la claudina 18.2 para el tratamiento del cáncer
MX378273B (es) Compuestos activos hacia bromodominios.
LT3283527T (lt) Kompleksinė terapija vėžio gydymui
IL270511A (en) Combination therapies using niraparib and pembrolizumab for treating cancer
LT2943192T (lt) Kasos vėžio gydymo būdai, apimantys paklitakselį ir gemcitabiną
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
MX2017015424A (es) Nanoparticulas para su uso como vacuna terapeutica.
MX380252B (es) Crenezumab para usarse en el tratamiento de enfermedad de alzheimer.
LT3458610T (lt) Krūties vėžio terapinis gydymas, remiantis c-maf būkle
PT3622953T (pt) Tratamento combinado do cancro
MX2023006415A (es) Anticuerpos, usos y metodos.
EA201691887A1 (ru) Лечение внутрипеченочных холестатических заболеваний
LT3168214T (lt) Pakeisti 2-tiokso-imidazolidin-4-onai ir jų spiro analogai, aktyvi priešvėžinė sudedamoji dalis, farmacinė kompozicija, medicininis paruošimas, prostatos vėžio gydymo būdas
MX2020009966A (es) Formas de dosificacion y usos terapeuticos de la l-4-cloro quinurenina.
LT3352857T (lt) T-dm1 atsparių, vėžiu sergančių pacientų gydymas junginiu syd985
EP3145510B8 (en) Treatment of diseases using combination of ultraviolet blood irradiation and antibiotics
BR112017005002A2 (pt) macropinocitose de anticorpos anti-cd46 humanos e agentes terapêuticos dirigidos contra o câncer.
BR112018002732A2 (pt) Agente terapêutico para tumor
DK3092039T3 (da) Hudcancerbehandling med strålingsterapi
UA99785U (uk) Застосування субстанції наночастинок срібла як протимікробного засобу при лікуванні гнійно-запальних захворювань щелепно-лицевої ділянки